Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the year ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results